Usual Adult Dose for Skin and Structure Infection

200 mg IV or orally once a day for 6 days

Use: For the treatment of acute bacterial skin and skin structure infections due to susceptible isolates of Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Streptococcus pyogenes, S agalactiae, S anginosus group (including S anginosus, S intermedius, and S constellatus), Enterococcus faecalis

Usual Pediatric Dose for Skin and Structure Infection

12 years or older: 200 mg IV or orally once a day for 6 days

Use: For the treatment of acute bacterial skin and skin structure infections due to susceptible isolates of S aureus (including methicillin-resistant and methicillin-susceptible isolates), S pyogenes, S agalactiae, S anginosus group (including S anginosus, S intermedius, and S constellatus), E faecalis

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: No adjustment recommended.
Peritoneal dialysis: Data not available

Other Comments

Administration advice:

• IV: Administer via IV infusion over 1 hour; do not administer as IV push or bolus. This drug is not for intra-arterial, IM, intrathecal, intraperitoneal, or subcutaneous administration.
• IV: Do not mix with other agents during administration; if the same IV line is used for sequential infusion of several drugs, flush the line with a compatible infusion solution before and after infusion of this drug.
• Do not adjust dose when switching from IV to oral administration (no adjustments needed).
• Oral: Administer with or without food; no dietary restrictions.
• Consult the manufacturer product information regarding missed doses.

• IV: Total time from reconstitution to administration should not exceed 24 hours at room temperature or refrigerated at 2C to 8C (36F to 46F); discard unused portion.

• IV formulation: Must be reconstituted and then diluted; the manufacturer product information should be consulted.

• Compatible diluents and IV solutions: Sterile Water for Injection; 0.9% Sodium Chloride Injection, USP
• Incompatible: Any solution containing divalent cations (e.g., calcium, magnesium), including Lactated Ringers Injection and Hartmann's Solution
• Limited data available on compatibility of this drug with other IV substances, additives, or other drugs; they should not be added to tedizolid single-dose vials or infused simultaneously.

• To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

• Read the US FDA-approved patient labeling (Patient Information).
• Avoid missing doses and complete the entire course of therapy.
• Consult physician at once if watery and bloody stools (with or without stomach cramps and fever) develop.
• Patients of childbearing potential: Notify healthcare provider of known/suspected pregnancy.